cjc-1295 ipamorelin clinical trial humans & Peptide Therapy CJC-1295 No DAC + Ipamorelin
Description
Smith AD
These may act as signaling metabolites with anti-tumor effects by engaging G-protein receptors and inhibiting class-I histone deacetylases, altering gene expression, and dampening PI3KAKT-mTOR signaling 354,355
In line with this, we found that none of these hits inhibited human cathepsin L at concentrations up to 10 M (Supplementary Fig
6.0%, respectively) [7]
doi: 10.3389/fimmu.2024.1390263
